$CTIX Recent Headlines Cellceutix jumps on QIDP tag

New Post Public Reply Private Reply Replies (0) Message Board
Stock_Tracker
$CTIX Recent Headlines

Cellceutix jumps on QIDP tag 1:23 p.m. Dec. 8, 2014 - Seeking Alpha
Cellceutix Brilacidin IND effective, Phase 2 to begin 9:31 a.m. Oct. 13, 2014 - Seeking Alpha
Regulatory Support Creates Opportunity For Antibiotic Makers Otonomy And Cellceutix 9:02 a.m. Sept. 25, 2014 - Seeking Alpha
Update: Cellceutix Calls Out To President Obama About Brilacidin 2:38 p.m. Sept. 21, 2014 - Seeking Alpha
10-K: CELLCEUTIX CORP 12:53 p.m. Sept. 15, 2014 - Edgar Online - (EDG = 10Q, 10K)
Update: Cellceutix's Antibiotic Brilacidin Should Move Share Price Before Kevetrin Or Prurisol 2:06 a.m. Sept. 14, 2014 - Seeking Alpha
The Antibiotic Resistance Triple Threat 1:05 p.m. Sept. 4, 2014 - Seeking Alpha
Cellceutix completes enrollment in Brilacidin trial 8:45 a.m. Aug. 19, 2014 - Seeking Alpha
Did The Medicines Company Trump Cellceutix And Others In A $1B-Plus Skin Infection Market? 10:38 a.m. Aug. 14, 2014 - Seeking Alpha
10-Q: CELLCEUTIX CORP 9:15 a.m. May 12, 2014 - Edgar Online - (EDG = 10Q, 10K)
Huge Opportunities Are Now Possible Due To Market Inefficiencies In Valuing Antibiotic Companies Such As Cubist, Durata, And Cellceutix 9:34 a.m. April 25, 2014 - Seeking Alpha
10-Q: CELLCEUTIX CORP 4:09 p.m. Feb. 10, 2014 - Edgar Online - (EDG = 10Q, 10K)
Cellceutix Is Significantly Undervalued Considering The Value Of Brilacidin 9:31 a.m. Jan. 28, 2014 - Seeking Alpha
Cellceutix Corp.: A Biotech With High Risk But High Reward 3:17 p.m. Jan. 2, 2014 - Wall St. Cheat Sheet
Cellceutix: An Undiscovered Company Set To Rise In 2014 9:06 a.m. Dec. 16, 2013 - Seeking Alpha
3 Innovative Biotech Companies Poised To Shine At TAP Partnership Conference 5:38 a.m. Nov. 19, 2013 - Seeking Alpha
10-Q: CELLCEUTIX CORP 5:06 p.m. Nov. 8, 2013 - Edgar Online - (EDG = 10Q, 10K)
10-K: CELLCEUTIX CORP 3:01 p.m. Sept. 30, 2013 - Edgar Online - (EDG = 10Q, 10K)
10-Q: CELLCEUTIX CORP 1:18 p.m. May 20, 2013 - Edgar Online - (EDG = 10Q, 10K)
Interview with CEO of Cellceutix Corporation: Leo Ehrlich 8:57 a.m. Nov. 15, 2011 - GuruFocus.com


Cellceutix: Prurisol(TM) for Psoriasis -- FDA Agrees That Phase 2 Study May Begin 7:41 a.m. Dec. 10, 2014 - Marketwired
Cellceutix Antibiotic Brilacidin Receives QIDP Designation From FDA 7:01 a.m. Dec. 8, 2014 - Marketwired
Cellceutix: December to Be Momentous Month in Company's History 7:02 a.m. Nov. 24, 2014 - Marketwired
These Medical Stocks Are Reaching A Fever Pitch Following Midterm Elections 9:54 a.m. Nov. 12, 2014 - ACCESSWIRE
Patient Enrollment in Cellceutix Phase 2 Clinical Trial of Brilacidin-OM for Oral Mucositis Targeted to Begin in December 2014 7:01 a.m. Nov. 11, 2014 - Marketwired
Cellceutix's New Chief Operating Officer Dr. James Alexander Addresses Shareholders 6:00 a.m. Oct. 31, 2014 - Marketwired
Cellceutix Announces Positive Top-Line Data From Phase 2b ABSSSI Trial; Single-Dose Brilacidin Comparable to 7-Days of Daptomycin 10:52 a.m. Oct. 23, 2014 - Marketwired
Cellceutix Investigational New Drug (IND) Application Becomes Effective, Selects First Site for Phase 2 Clinical Trial of New Treatment for Oral Mucositis 8:02 a.m. Oct. 13, 2014 - Marketwired
Cellceutix Provides Update to Shareholders 11:30 a.m. Sept. 24, 2014 - Marketwire
Cellceutix to President Obama: We Have the Tools and Will Rise Up to the Challenge to Prevent Antibiotic Resistant Bacteria Becoming a Serious Threat to Public Health 6:15 a.m. Sept. 19, 2014 - Marketwire
Cellceutix Provides Initial Observations of Completed ABSSSI Phase 2b Trial; Company Submits Investigational New Drug Application to FDA for Phase 2 Trial of Brilacidin-OM for Oral Mucositis 2:01 p.m. Sept. 9, 2014 - Marketwire
Cellceutix to Present at Rodman & Renshaw's 16th Annual Global Investment Conference 10:17 a.m. Sept. 5, 2014 - Marketwire
Cellceutix Appoints Dr. Barry Schechter to Board of Directors as Company Focuses on Meeting Requirements for Stock Exchange Uplisting 6:01 a.m. Sept. 2, 2014 - Marketwire
Cellceutix Completes Enrollment in Phase 2b Clinical Trial of Brilacidin for Acute Bacterial Skin and Skin Structure Infections (ABSSSI) 7:31 a.m. Aug. 19, 2014 - Marketwire
Cellceutix Prepares for Phase 2 Clinical Trial of Brilacidin-OM for Oral Mucositis 6:01 a.m. Aug. 11, 2014 - Marketwire
Cellceutix Anti-Psoriasis Drug Prurisol Meets Primary Endpoint of Clinical Trial 5:04 a.m. Aug. 8, 2014 - Marketwire
Cellceutix Believes Brilacidin on Track to Help U.S. Avoid Falling Into Post-Antibiotic Era; Completion of Enrollment in Phase 2b Trial for Acute Bacterial Skin and Skin Structure Infections Expected This Month 6:01 a.m. Aug. 4, 2014 - Marketwire
Cellceutix Announces Breakthrough in the Formulation of Its Novel Antibiotic Brilacidin(TM), Plans Studies to Treat Diabetic Foot Ulcers 6:01 a.m. July 14, 2014 - Marketwire
Cellceutix Brilacidin ABSSSI Trial Gets Positive Review by Data Safety Monitoring Board; Best Possible Outcome, No Treatment-Related Serious Adverse Events (SAEs) 6:00 a.m. July 7, 2014 - Marketwire
Cellceutix Anti-Fungal Compounds Awarded $1.5 Million SBIR Grant 6:01 a.m. June 23, 2014 - Marketwire

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Aurra Markets Wins 'Most Transparent Broker' Award 2026

Updated Category News Views 1

Spotlight on Transparency in Trading Alright, so Aurra Markets snagged the 'Most Transparent Broker' award at the Money Expo in Mumbai this year. From the greasy streets of trading floors to the polished halls of Jio World Convention Centre, transparency is one of those golden words you hear tossed around, but like finding a needle in a haystack, it’s not always easy to...

Continue Reading
Spencer Spirit Completes Hot Topic Acquisition

Updated Category News Views 1

Merging Forces in Retail In the latest retail reshuffle, Spencer Spirit Holdings has wrapped up its acquisition of Hot Topic, Inc., alongside its eclectic sub-brands: BoxLunch and Her Universe. This move doubles down on Spencer Spirit's ambitions to tighten its grip on the mall-based specialty retail game. If you're an investor looking for a shake-up that could redefine...

Continue Reading
Codoxo Snags 2026 Award for AI Payment Innovation

Updated Category News Views 2

Revolutionizing Healthcare Payment with AI Ah, healthcare and payments—two things that can make even the most patient folks lose their cool. But here comes Codoxo, shaking up this landscape with its Point Zero Payment Integrity solution, and someone's finally giving them the nod they deserve. For those of us who have been in the game for a while, this announcement is...

Continue Reading
ITP Media's Bold Move: Ready for Asian Market Surge

Updated Category News Views 1

Pushing Boundaries: ITP Media Group Eyes Asia ITP Media Group isn't here to tiptoe around the media market; they're diving headfirst with the recent takeover of Heart Media Group. A bold move, some might say, in this volatile world of media mergers and acquisitions. But let's break down what this really means. A Strategic Bet on Luxury To start, ITP Media is beefing up...

Continue Reading
XTransfer Revs Up Expansion in the UAE Market

Updated Category News Views 1

In the nitty-gritty world of B2B payments, securing a spot in a powerhouse like the UAE is no small potatoes. XTransfer just snagged an in-principle nod from the UAE Central Bank for a Retail Payment Services Licence, and that's got to feel like sweet validation for a company that's aggressively pushing its regulatory map beyond corners it's already conquered. Eyeing the...

Continue Reading
Immunic Pushes Boundaries in MS with Vidofludimus

Updated Category News Views 2

Shaking Things Up in Multiple Sclerosis Therapy There's no telling how often the biotech sector tosses around the term 'game-changer,' but when Immunic's name comes up, more ears are perking up these days. The New York-based firm, waving the Nasdaq: IMUX flag, is lining up a virtual shindig come September 9, 2026, and for anyone invested in multiple sclerosis (MS) or...

Continue Reading
GoPro's $1.14 Buyout Scrutinized: Fair Value Debate

Updated Category News Views 2

Unpacking the GoPro Buyout Announcement There's some commotion brewing in the investor world, especially if you're clutching onto shares of GoPro (NASDAQ:GPRO). A $1.14 per share buyout has hit the spotlight, and folks are asking if this deal is kosher, particularly when there's $285 million on the line. Does the price truly reflect what GoPro's worth? Ademi LLP is...

Continue Reading
Epson and STOPware Reinvent Visitor Badges for Security

Updated Category News Views 12

Gone are the days when a flimsy monochrome badge was all that stood between a visitor and unrestricted access. Today, Epson and STOPware rock the boat with their new collaboration, offering a game-changing approach to security with full-color badge printing. This isn't just a vanity upgrade; it's about real security enhancement creating immediate visual cues. Shifting the...

Continue Reading
GenesisFX Rolls Out Live Leaderboards, Boosts Social Trading

Updated Category News Views 5

Traders buckle up! GenesisFX Markets just kicked open a new chapter in forex and CFD trading with their Live Leaderboards and beefed-up social trading tools. What's the commotion about? Well, that's your hook. These leaderboards are the newest addition to their ecosystem, paired with some serious social trading muscle. As Arkadiusz Bujalski, the Head of Ops and System...

Continue Reading
stackArmor Secures FedRAMP High: A Strategic Milestone

Updated Category News Views 2

stackArmor: Carving a Niche in Federal Cybersecurity Hey, not every day you wake up to find a company carving its niche in federal cybersecurity quite the way stackArmor is doing. They've recently got their hands on that elusive FedRAMP High authorization for The Armory. What's this mean in English? Well, for starters, these guys are showing they're serious about...

Continue Reading

Top 5 Most Recently Viewed Articles

Roche's Evrysdi Tablet Revolutionizes SMA Treatment Options

Updated Category News Views 195

Roche's Evrysdi Tablet Revolutionizes SMA Treatment Options Roche has recently made a remarkable advancement in the field of spinal muscular atrophy (SMA) treatment with the approval of the Evrysdi® tablet by the European Commission. This new formulation is not just another medication; it symbolizes a significant leap towards enhancing the quality of life for individuals...

Continue Reading
IVX Health Celebrates Recognition as Top Workplace in Healthcare

Updated Category News Views 138

IVX Health Honored by Modern Healthcare IVX Health has been recognized by Modern Healthcare as one of the Best Places to Work in Healthcare for 2024. This esteemed honor reflects the company's commitment to excellence within the healthcare sector. The annual program highlights 150 distinguished organizations that excel in fostering a supportive and engaging workplace, and...

Continue Reading
NAMI Strengthens Leadership to Address Mental Health Challenges

Updated Category News Views 174

New Board Leadership at the National Alliance on Mental Illness The National Alliance on Mental Illness (NAMI) has announced significant changes in its leadership to tackle the growing mental health crisis in the United States. This newly elected board for the 2025-2026 term comprises dedicated individuals with personal and community ties to mental health advocacy,...

Continue Reading
In-Depth Insights into Depression Treatment Market Trends

Updated Category News Views 208

Overview of the Depression Treatment Market The depression treatment market is seeing a notable surge fueled by increasing mental health awareness and a rising number of individuals affected by this serious condition. With over 280 million people globally struggling with depression, the ongoing advancements in treatment options, including innovative antidepressants and...

Continue Reading